(CPRX) Catalyst Pharmaceuticals - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 3.828m USD | Total Return: 25.9% in 12m

Muscle Disease Drugs, Epilepsy Treatments, Rare Disease Medicines
Total Rating 63
Safety 78
Buy Signal 0.99
Biotechnology
Industry Rotation: -7.0
Market Cap: 3.83B
Avg Turnover: 79.4M
Risk 3d forecast
Volatility37.8%
VaR 5th Pctl6.21%
VaR vs Median-0.13%
Reward TTM
Sharpe Ratio0.81
Rel. Str. IBD80.5
Rel. Str. Peer Group53.8
Character TTM
Beta0.808
Beta Downside0.647
Hurst Exponent0.364
Drawdowns 3y
Max DD27.29%
CAGR/Max DD1.47
CAGR/Mean DD4.19
EPS (Earnings per Share) EPS (Earnings per Share) of CPRX over the last years for every Quarter: "2021-03": 0.07, "2021-06": 0.11, "2021-09": 0.1, "2021-12": 0.09, "2022-03": 0.12, "2022-06": 0.2, "2022-09": 0.2, "2022-12": 0.22, "2023-03": 0.26, "2023-06": 0.53, "2023-09": -0.29, "2023-12": 0.31, "2024-03": 0.19, "2024-06": 0.33, "2024-09": 0.35, "2024-12": 0.44, "2025-03": 0.45, "2025-06": 0.41, "2025-09": 0.42, "2025-12": 0.68, "2026-03": 0.79,
EPS CAGR: 49.32%
EPS Trend: 79.7%
Last SUE: 1.26
Qual. Beats: 3
Revenue Revenue of CPRX over the last years for every Quarter: 2021-03: 30.205, 2021-06: 36.365, 2021-09: 35.954, 2021-12: 38.309, 2022-03: 43.089, 2022-06: 53.113, 2022-09: 57.244, 2022-12: 60.757, 2023-03: 85.366, 2023-06: 99.582, 2023-09: 102.688, 2023-12: 110.568, 2024-03: 98.509, 2024-06: 122.71, 2024-09: 128.695, 2024-12: 141.82, 2025-03: 141.421, 2025-06: 146.563, 2025-09: 148.392, 2025-12: 152.613, 2026-03: 149.39,
Rev. CAGR: 26.87%
Rev. Trend: 97.5%
Last SUE: 0.27
Qual. Beats: 0

Warnings

No concerns identified

Tailwinds

Supp Ema8, Supp Ema20, Idiosyncratic Leader

Description: CPRX Catalyst Pharmaceuticals

Catalyst Pharmaceuticals (CPRX) is a commercial-stage biotechnology firm specializing in the development and distribution of therapies for rare neuromuscular and neurological conditions. Its primary portfolio includes Firdapse for Lambert-Eaton myasthenic syndrome, Fycompa for seizure disorders, and AGAMREE for Duchenne muscular dystrophy.

The company operates within the orphan drug sector, a business model that benefits from extended market exclusivity and streamlined regulatory pathways intended to incentivize research into diseases with small patient populations. This niche focus often allows for high pricing power and lower competition compared to broad-market pharmaceuticals.

Strategic growth is managed through licensing agreements with established entities such as BioMarin Pharmaceutical and Endo Ventures. You can find more detailed financial metrics for CPRX by visiting ValueRay. Founded in 2002 and headquartered in Florida, Catalyst continues to expand its commercial footprint through the acquisition of late-stage neurological assets.

Headlines to Watch Out For
  • Firdapse market expansion and patient enrollment drive long-term revenue growth
  • AGAMREE commercial launch success determines near-term specialty pharmacy sales performance
  • Patent litigation outcomes and generic competition threats impact long-term cash flows
  • Fycompa integration and prescription volume growth diversify the rare disease portfolio
  • Strategic acquisitions of orphan drug assets influence capital allocation and valuation
Piotroski VR-10 (Strict) 3.5
Net Income: 221.3m TTM > 0 and > 6% of Revenue
FCF/TA: 0.18 > 0.02 and ΔFCF/TA -11.30 > 1.0
NWC/Revenue: 135.4% < 20% (prev 107.4%; Δ 27.98% < -1%)
CFO/TA 0.18 > 3% & CFO 208.2m > Net Income 221.3m
Net Debt (-753.2m) to EBITDA (313.7m): -2.40 < 3
Current Ratio: 7.10 > 1.5 & < 3
Outstanding Shares: last quarter (126.9m) vs 12m ago -0.04% < -2%
Gross Margin: 82.32% > 18% (prev 0.86%; Δ 8.15k% > 0.5%)
Asset Turnover: 58.06% > 50% (prev 58.83%; Δ -0.77% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' 10.00
A: 0.70 (Total Current Assets 940.4m - Total Current Liabilities 132.4m) / Total Assets 1.15b
B: 0.46 (Retained Earnings 523.3m / Total Assets 1.15b)
C: 0.27 (EBIT TTM 275.4m / Avg Total Assets 1.03b)
D: 3.88 (Book Value of Equity 523.5m / Total Liabilities 134.9m)
Altman-Z'' = 11.98 = AAA
Beneish M -2.53
DSRI: 1.63 (Receivables 131.3m/72.3m, Revenue 597.0m/534.6m)
GMI: 1.05 (GM 82.32% / 86.11%)
AQI: 0.74 (AQ_t 0.18 / AQ_t-1 0.24)
SGI: 1.12 (Revenue 597.0m / 534.6m)
TATA: 0.01 (NI 221.3m - CFO 208.2m) / TA 1.15b)
Beneish M = -2.53 (Cap -4..+1) = A
What is the price of CPRX shares?

As of May 26, 2026, the stock is trading at USD 31.26 with a total of 1,992,600 shares traded.
Over the past week, the price has changed by +0.26%, over one month by +6.80%, over three months by +25.74% and over the past year by +25.85%.

Is CPRX a buy, sell or hold?

Catalyst Pharmaceuticals has received a consensus analysts rating of 4.86. Therefore, it is recommended to buy CPRX.

  • StrongBuy: 6
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the CPRX price?
Analysts Target Price 33.3 6.5%
Catalyst Pharmaceuticals (CPRX) - Fundamental Data Overview as of 23 May 2026
Market Cap USD = 3.83b (3.83b USD * 1.0 USD.USD)
P/E Trailing = 18.0809
P/E Forward = 12.8535
P/S = 6.4126
P/B = 3.7765
Revenue TTM = 597.0m USD
EBIT TTM = 275.4m USD
EBITDA TTM = 313.7m USD
Long Term Debt = 2.23m USD (estimated: total debt 2.68m - short term 446k)
Short Term Debt = 446k USD (from shortTermDebt, last quarter)
Debt = 2.68m USD (from shortLongTermDebtTotal, last quarter) (leases 2.68m already included)
Net Debt = -753.2m USD (calculated: Debt 2.68m - CCE 755.9m)
Enterprise Value = 3.07b USD (3.83b + Debt 2.68m - CCE 755.9m)
 Interest Coverage Ratio = unknown (Ebit TTM 275.4m / Interest Expense TTM 0.0)
 EV/FCF = 14.77x (Enterprise Value 3.07b / FCF TTM 208.1m)
FCF Yield = 6.77% (FCF TTM 208.1m / Enterprise Value 3.07b)
FCF Margin = 34.86% (FCF TTM 208.1m / Revenue TTM 597.0m)
Net Margin = 37.08% (Net Income TTM 221.3m / Revenue TTM 597.0m)
Gross Margin = 82.32% ((Revenue TTM 597.0m - Cost of Revenue TTM 105.5m) / Revenue TTM)
Gross Margin QoQ = 83.82% (prev 82.91%)
Tobins Q-Ratio = 2.68 (Enterprise Value 3.07b / Total Assets 1.15b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 2.68m)
Taxrate = 24.33% (20.5m / 84.2m)
NOPAT = 208.4m (EBIT 275.4m * (1 - 24.33%))
Current Ratio = 7.10 (Total Current Assets 940.4m / Total Current Liabilities 132.4m)
Debt / Equity = 0.00 (Debt 2.68m / totalStockholderEquity, last quarter 1.01b)
Debt / EBITDA = -2.40 (Net Debt -753.2m / EBITDA 313.7m)
Debt / FCF = -3.62 (Net Debt -753.2m / FCF TTM 208.1m)
Total Stockholder Equity = 935.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 21.52% (Net Income 221.3m / Total Assets 1.15b)
RoE = 23.65% (Net Income TTM 221.3m / Total Stockholder Equity 935.8m)
RoCE = 29.36% (EBIT 275.4m / Capital Employed (Equity 935.8m + L.T.Debt 2.23m))
RoIC = 26.55% (NOPAT 208.4m / Invested Capital 785.0m)
WACC = 8.81% (E(3.83b)/V(3.83b) * Re(8.82%) + D(2.68m)/V(3.83b) * Rd(0.0%) * (1-Tc(0.24)))
Discount Rate = 8.82% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 73.33 | Cagr: 4.98%
[DCF] Terminal Value 71.37% ; FCFF base≈231.9m ; Y1≈203.4m ; Y5≈164.3m
[DCF] Fair Price = 26.17 (EV 2.45b - Net Debt -753.2m = Equity 3.20b / Shares 122.4m; r=8.81% [WACC]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: 79.69 | EPS CAGR: 49.32% | SUE: 1.26 | # QB: 3
Revenue Correlation: 97.48 | Revenue CAGR: 26.87% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.69 | Chg30d=+2.59% | Revisions=+20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.73 | Chg30d=+2.10% | Revisions=+20% | Analysts=4
EPS current Year (2026-12-31): EPS=2.86 | Chg30d=+0.26% | Revisions=+20% | GrowthEPS=+5.1% | GrowthRev=+6.4%
EPS next Year (2027-12-31): EPS=3.14 | Chg30d=+0.64% | Revisions=+20% | GrowthEPS=+9.7% | GrowthRev=+12.0%
[Analyst] Revisions Ratio: +20%